Identification of snoRNA SNORA71A as a Novel Biomarker in Prognosis of Hepatocellular Carcinoma.
Identification of snoRNA SNORA71A as a Novel Biomarker in Prognosis of Hepatocellular Carcinoma.
复制标题
鉴定 snoRNA SNORA71A 作为肝细胞癌预后的新型生物标志物
DOI：
10.1155/2020/8879944
复制
发表时间：
2020
期刊：
影响因子：
--
通讯作者：
Wang W
中科院分区：
文献类型：
--
作者：
Ding Y;Sun Z;Zhang S;Zhou L;Xu Q;Zhou D;Li Y;Han X;Xu H;Bai Y;Xu C;Ding H;Ge Y;Wang W
背景小核仁RNA（snoRNA）已被证明在多种细胞生理过程中发挥重要作用。最近，人们发现snoRNA SNORA71A的失调与多种恶性肿瘤的发生有关。然而，SNORA71A 在肝细胞癌 (HCC) 中的新作用尚不清楚。在本研究中，我们旨在探讨 SNORA71A 在 HCC 中的表达及其潜在意义。方法通过实时定量PCR检测细胞系和临床标本中SNORA71A的表达。然后，将所有入组的HCC患者分为低SNORA71A表达亚组和高SNORA71A表达亚组，然后通过各自的统计分析方法对临床特征和生存结果进行比较。结果 SNORA71A 在 SK-HEP-1 (P = 0.001)、Huh-7 (P < 0.001)、Hep3B (P < 0.001) 和临床 HCC 标本 (P = 0.006) 中显着下调。比较SNORA71A表达亚组之间的临床特征，发现SNORA71A低表达与肿瘤直径大、病灶多、包膜侵犯、肿瘤分化差和TNM分期显着相关（P < 0.05）。此外，发现SNORA71A表达较低的HCC患者术后肿瘤复发风险较高（中位时间：9.5个月与35.2个月；低与高；P < 0.001），总生存期较差（中位时间：36.8与52.9个月；低与高；P < 0.001）。此外，SNORA71A表达是无瘤生存（HR = 0.450；95% CI [0.263-0.770]；P = 0.004）和长期生存（HR = 0.289；95% CI [0.127-0.657]；P = 0.003）的独立危险因素。结论 我们的研究首次证明 SNORA71A 的下调可以作为 HCC 患者临床评估和预后预测的新型生物标志物。
Background Small nucleolar RNAs (snoRNAs) have been proved to play important roles in various cellular physiological process. Recently, dysregulation of snoRNA SNORA71A has been found involved in tumorigenesis of various malignant cancers. However, the emerging effects of SNORA71A in hepatocellular carcinoma (HCC) remain largely unclear. In this study, we aimed to explore the SNORA71A expression and its underlying significance in HCC. Methods Expression of SNORA71A in cell lines and clinical specimens was measured by quantitative real-time PCR. Then, all enrolled HCC patients were divided into low and high SNORA71A expression subgroups and then they were compared in the aspects of clinical features as well as survival outcome by respective statistical analysis methods. Results SNORA71A was significantly downexpressed in SK-HEP-1 (P = 0.001), Huh-7 (P < 0.001), Hep3B (P < 0.001), and clinical HCC specimens (P = 0.006). Comparing the clinical features between SNORA71A expression subgroups, it showed that low SNORA71A expression was significantly associated with large tumor diameter, multiple lesions, capsular invasion, bad tumor differentiation, and TNM stage (P < 0.05). Furthermore, it was found that HCC patients with lower SNORA71A expression had higher risk in postoperative tumor relapse (median time: 9.5 vs. 35.2 months; low vs. high; P < 0.001) and poor overall survival (median time: 36.8 vs. 52.9 months; low vs. high; P < 0.001). Besides, SNORA71A expression served as independent risk factors for tumor-free (HR = 0.450; 95% CI [0.263-0.770]; P = 0.004) and long-term survival (HR = 0.289; 95% CI [0.127-0.657]; P = 0.003). Conclusions Our study for the first time demonstrated that downregulation of SNORA71A could serve as a novel biomarker for clinical assessment and prognostic prediction of HCC patients.
登录
查看更多内容
肝硬化患者的肝细胞癌筛查与癌症相关的死亡率降低之间没有关联。
影响因子：
29.4
作者：
Moon AM;Weiss NS;Beste LA;Su F;Ho SB;Jin GY;Lowy E;Berry K;Ioannou GN
通讯作者：
Ioannou GN
影响因子：
3.5
作者：
Dong, Xue-Yuan;Rodriguez, Carmen;Dong, Jin-Tang
通讯作者：
Dong, Jin-Tang
影响因子：
37.3
作者：
Xu G;Yang F;Ding CL;Zhao LJ;Ren H;Zhao P;Wang W;Qi ZT
通讯作者：
Qi ZT
影响因子：
2.9
作者：
Zhang, BH;Yang, BH
通讯作者：
Yang, BH
影响因子：
10.5
作者：
Ganot, P;CaizerguesFerrer, M;Kiss, T
通讯作者：
Kiss, T